U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07713485) titled 'Study of XmAb412 in Healthy Participants' on July 14.
Brief Summary: This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
Study Start Date: July 13
Study Type: INTERVENTIONAL
Condition:
Not Applicable - Healthy Adult Participants
Intervention:
DRUG: XmAb412 Monoclonal Bispecific Antibody
Monoclonal Bispecific Antibody
DRUG: Placebo
Placebo
Recruitment Status: RECRUITING
Sponsor: Xencor, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....